Skip to main content
OpenTrials
Completed

NCT Number: NCT04891419

JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population

The objectives of this study are to evaluate the safety and effectiveness of JUVÉDERM® VOLUMA® with Lidocaine injectable gel in adult Chinese population seeking correction of temple hollowing.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Temple Hollowing

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Beijing Hospital /ID# 233582, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be 18 or over, at the time of signing the ICF
  • Participants seeking improvement of temple hollowing
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol
  • Written informed consent from the participant has been obtained prior to any study-related procedures
  • Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable
  • Is able to complete effectiveness self-assessments without the use of glasses (contact lens use is acceptable if they will be used for all participant self-assessments)

Exclusion criteria

  • Temple hollowing due to trauma, congenital malformations, or lipodystrophy, either congenital or acquired
  • Has experienced trauma to the temple area within 6 months before enrollment or has residual deficiencies, deformities, or scarring
  • Temporal arteritis or history of temporal arteritis
  • Temporomandibular joint dysfunction or any other jaw issues
  • Recurrent temporal headaches such as temporal tendinitis migraine
  • Active or recurrent inflammation or infection in either eye
  • Tendency to develop hypertrophic scarring
  • Active autoimmune disease
  • History of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), HA products, or Streptococcal protein
  • Current cutaneous or mucosal inflammatory or infectious processes (e.g. acne, herpes), abscess, an unhealed wound, or a cancerous or precancerous lesion, above the subnasal
  • Prior facial reconstructive surgeries, facelift, or browlift as well as surgeries on the temple area (eg, biopsy)
  • Fat injection or permanent facial implants anywhere in the face
  • Semipermanent soft-tissue filler treatment in the temple or mid-face within 36 months before enrollment
  • Temporary dermal filler injections above the subnasale within 12 months before enrollment
  • Mesotherapy or cosmetic facial procedures above the subnasale within 6 months before enrollment (examples of mesotherapy or cosmetic facial procedures are laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, or other ablative procedures.
  • Injections in the nasolabial fold are acceptable only if done at least 3 months prior to enrollment
  • Botulinum toxin treatment above the subnasale within 6 months before enrollment
  • Has braces or other orthodontics
  • Not eligible for this study if participants have begun using any new over the counter or prescription oral or tropical, anti-wrinkle products above the subnasale within 30 days before enrollment. Participants who have been on a regimen of such products for at least 30 days are eligible for the study if they intend to continue their regimen throughout the study
  • Is on a regimen of anti-coagulation therapy (eg, warfarin, clopidogrel)
  • Has tattoos, piercings, facial hair, or scars above and including the subnasale that would interfere with visual assessment of the temple
  • Females who are pregnant, nursing, or planning a pregnancy
  • Plans a significant weight change (more than 10% of body weight) during the study

Treatment and study plan

JUVÉDERM® VOLUMA® with Lidocaine

Device

JUVÉDERM® VOLUMA® with Lidocaine injectable gel

Primary outcomes

  1. Number of Participants With Adverse Events

    Time frame: Up to 14 Months

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug and no more than 30 days after the last dose of the study drug.

  2. Participants With at Least a 1-Point Improvement (Decrease) in Temple as Assessed by the Evaluating Investigator (EI) Using the Allergan Temple Hollowing Scale (ATHS)

    Time frame: Change from Baseline to Month 6

    The Evaluating Investigator will assess the participant's temple hollowing using the ATHS 5-point scale where: 0=convex, rounded temple to 4=severe, deeply recessed, sunken appearance. A 1-point decrease from Baseline indicates improvement.

Secondary outcomes

  1. Change From Baseline on Rasch Transformed Score of FACE-Q Satisfaction With Temples Questionnaire at Month 6

    Time frame: Change from Baseline to Month 6

    Participant-assessed satisfaction using the 12-item FACE-Q Satisfaction with Temples Questionnaire was measured on a 4-point scale where 1=very dissatisfied, 2=somewhat dissatisfied, 3=somewhat satisfied, and 4=very satisfied. The responses to the items were converted to a 100-point Rasch transformed score ranging from 0 (worst) to 100 (best). Higher scores indicate higher satisfaction. A positive change from Baseline indicates improvement.

  2. Change From Baseline on Rasch Transformed Score of FACE-Q Satisfaction With Facial Appearance Questionnaire at Month 6

    Time frame: Change from baseline to Month 6

    Participant-assessed satisfaction using the 10-item FACE-Q Satisfaction with Facial Appearance Questionnaire was measured on a 4-point scale where 1=very dissatisfied, 2=somewhat dissatisfied, 3=somewhat satisfied, and 4=very satisfied. The responses to the items were converted to a 100-point Rasch transformed score ranging from 0 (worst) to 100 (best). Higher scores indicate higher satisfaction. A positive change from Baseline indicates improvement.

  3. Participants "Improved" or "Much Improved" as Self-assessed by Participant Using the Global Aesthetic Improvement Scale (GAIS)

    Time frame: Month 6

    Participant will assess temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and-2=much worse.

  4. Participants "Improved" or "Much Improved" as Assessed by the Evaluating Investigator Using the Global Aesthetic Improvement Scale (GAIS)

    Time frame: Month 6

    The Evaluating Investigator will assess the participant's temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and-2=much worse.

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Official study title

A Multicenter, Evaluator-blinded, Randomized, No-treatment Controlled Study to Evaluate the Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
May 18, 2021
Registry last updated
Dec 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.